We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Synthetic RNA Blocks Tumor Formation in Cancer Model

By LabMedica International staff writers
Posted on 27 Nov 2017
Print article
Image: Cells treated with a chemical carcinogen show severe liver cancer development. In cells treated with the same dosage of a chemical carcinogen and given synthetic dsRNA treatment at the pre-cancer stage, tumor suppression occurred (Photo courtesy of the University of California, San Diego).
Image: Cells treated with a chemical carcinogen show severe liver cancer development. In cells treated with the same dosage of a chemical carcinogen and given synthetic dsRNA treatment at the pre-cancer stage, tumor suppression occurred (Photo courtesy of the University of California, San Diego).
A team of cancer researchers demonstrated that the synthetic double-stranded RNA (dsRNA), polyinosinic-polycytidylic acid (pIC), could block the formation of liver tumors in a mouse model.

Liver cancer has emerged as the second most deadly malignant disease (more than 780,000 new cases and 740,000 deaths worldwide each year), with no efficient targeted or immune therapeutic agents yet available.

Investigators at the University of California, San Diego (USA) were working on the molecular mechanisms underlying the pathogenicity of liver cancer when they found that the synthetic dsRNA pIC, which is an immunostimulant that is used in the form of its sodium salt to simulate viral infections, significantly enhanced a variety of anti-tumor innate immune functions.

They reported in the November 14, 2017, online edition of the journal Cell Reports that injection of pIC at the pre-cancer stage robustly suppressed formation of liver tumors that had been induced either by chemical carcinogens or by Pten loss with associated fatty liver disease. The dsRNA inhibited liver cancer initiation, apparently by boosting multiple anti-tumor activities of innate immunity, including induction of immunoregulatory cytokines, activation of NK (natural killer) cells and dendritic cells, and reprogramming of macrophage polarization.

"The findings suggest that the drug may prevent liver cancer. We have more work to do, but we could make a real impact at a time when liver cancer rates are increasing," said senior author Dr. Gen-Sheng Feng, professor of pathology and molecular biology at the University of California, San Diego. "There is a large population living with chronic liver disease who are at high risk of developing cancer. If we can develop a vaccine that prevents tumor formation or a therapeutic combination that stops existing cancer from growing, we could reduce the rapid increase of liver cancer rates."

"The liver has unique immune tolerance, which is why existing treatments, including immunotherapy, have little to no lasting effects on liver cancer," said Dr. Feng. "We were initially performing gene deletion to investigate how different types of cells communicate in the liver to promote or suppress cancer development when we found that this synthetic double-stranded RNA prevented liver cancer from initiating by harnessing the body's own innate immune system."

Related Links:
University of California, San Diego

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.